Ironwood Pharmaceuticals Inc (IRWD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ironwood Pharmaceuticals Inc (IRWD) has a cash flow conversion efficiency ratio of -0.180x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($47.58 Million) by net assets ($-264.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ironwood Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Ironwood Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ironwood Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Ironwood Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ironwood Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sercomm Corp
TW:5388
|
-0.061x |
|
Chipsea Technologies Shenzhen Corp Ltd
SHG:688595
|
-0.042x |
|
Chong Hong Construction Co Ltd
TW:5534
|
0.088x |
|
Hangzhou Dadi Haiyang Environmental Protection Co. Ltd.
SHE:301068
|
N/A |
|
Changshu Automotive Trim Co
SHG:603035
|
-0.004x |
|
CFM Indosuez Wealth SA
PA:MLCFM
|
-1.211x |
|
Zhejiang Yingfeng Technology Co Ltd
SHG:605055
|
N/A |
|
Ackerstein Group Ltd
TA:ACKR
|
0.022x |
Annual Cash Flow Conversion Efficiency for Ironwood Pharmaceuticals Inc (2007–2024)
The table below shows the annual cash flow conversion efficiency of Ironwood Pharmaceuticals Inc from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see IRWD stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-301.33 Million | $103.55 Million | -0.344x | +35.12% |
| 2023-12-31 | $-346.30 Million | $183.43 Million | -0.530x | -226.22% |
| 2022-12-31 | $652.38 Million | $273.76 Million | 0.420x | -2.91% |
| 2021-12-31 | $605.91 Million | $261.89 Million | 0.432x | -83.96% |
| 2020-12-31 | $62.64 Million | $168.84 Million | 2.695x | +2443.52% |
| 2019-12-31 | $-93.25 Million | $10.72 Million | -0.115x | -131.86% |
| 2018-12-31 | $-196.37 Million | $-70.88 Million | 0.361x | +103.57% |
| 2017-12-31 | $9.85 Million | $-99.56 Million | -10.110x | -2552.05% |
| 2016-12-31 | $66.72 Million | $-25.43 Million | -0.381x | +66.09% |
| 2015-12-31 | $95.12 Million | $-106.93 Million | -1.124x | +36.02% |
| 2014-12-31 | $88.55 Million | $-155.57 Million | -1.757x | +75.43% |
| 2013-12-31 | $38.23 Million | $-273.36 Million | -7.151x | -1379.39% |
| 2012-12-31 | $144.05 Million | $-69.63 Million | -0.483x | +29.42% |
| 2011-12-31 | $109.86 Million | $-75.24 Million | -0.685x | -60.93% |
| 2010-12-31 | $159.55 Million | $-67.90 Million | -0.426x | -3275.65% |
| 2009-12-31 | $-298.34 Million | $-4.00 Million | 0.013x | -89.05% |
| 2008-12-31 | $-230.41 Million | $-28.20 Million | 0.122x | +222.94% |
| 2007-12-31 | $-178.37 Million | $-6.76 Million | 0.038x | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as wel… Read more